25.43
-0.44 (-1.70%)
| Penutupan Terdahulu | 25.87 |
| Buka | 25.79 |
| Jumlah Dagangan | 2,127,736 |
| Purata Dagangan (3B) | 2,149,106 |
| Modal Pasaran | 2,805,826,304 |
| Harga / Jualan (P/S) | 195.72 |
| Harga / Buku (P/B) | 9.98 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Operasi (TTM) | -1,525.50% |
| EPS Cair (TTM) | -3.01 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 184.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.55% |
| Nisbah Semasa (MRQ) | 10.49 |
| Aliran Tunai Operasi (OCF TTM) | -152.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -117.16 M |
| Pulangan Atas Aset (ROA TTM) | -33.54% |
| Pulangan Atas Ekuiti (ROE TTM) | -69.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Immunome, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.13 |
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 11.48% |
| % Dimiliki oleh Institusi | 83.28% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ecor1 Capital, Llc | 30 Sep 2025 | 4,079,415 |
| Jefferies Financial Group Inc. | 30 Sep 2025 | 2,100,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (Evercore ISI Group, 57.30%) | Beli |
| Median | 34.00 (33.70%) | |
| Rendah | 31.00 (Wedbush, 21.90%) | Beli |
| Purata | 34.50 (35.67%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 21.62 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 15 Jan 2026 | 31.00 (21.90%) | Beli | 22.85 |
| Evercore ISI Group | 16 Dec 2025 | 40.00 (57.29%) | Beli | 23.48 |
| Guggenheim | 16 Dec 2025 | 35.00 (37.63%) | Beli | 23.48 |
| Lake Street | 16 Dec 2025 | 32.00 (25.84%) | Beli | 23.48 |
| Truist Securities | 01 Dec 2025 | 36.00 (41.57%) | Beli | 18.32 |
| Stephens & Co. | 17 Nov 2025 | 33.00 (29.77%) | Beli | 18.13 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |